Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01710605 : Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers
PhasePhase 3
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Women with metastatic ductal adenocarcinoma breast cancer

- 18 years old or more

- Hormone receptors positive breast cancer (ER+ and/or PR+) on the last pathological
analysis available.

- Acceptable patient's clinical situation compatible with chemotherapy or
hormonotherapy administration

- PS <4

- Life expectancy > 3 months

- Evidence of measurable or evaluable disease (RECIST 1.1 criteria)in the 28 days
before selection

- Information of the patient and signature of the informed consent form

Exclusion Criteria:

- Patient treated by chemotherapy or hormonotherapy for their metastatic disease
(treatment failure under adjuvant hormonotherapy are accepted)

- Her2 positive breast cancer

- History of other stage II or III cancer in the 5 years. History of other metastatic
cancer (whatever the time between the two cancers).

- Persons deprived of their freedom or under guardianship.

- Women unable to comply with the medical follow-up of the study for geographical,
social or mental reasons.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557